Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company's performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon's first company-developed biosimilar in Japan.
Our advancement in biotechnology has been a key development for Gedeon Richter this year as we move forward in our transition to become a truly specialty pharmaceutical manufacturer
What were your main motivations to join Ipsen as chief business officer 16 months ago? I have worked in pharma for over 28 years across France, Portugal, Germany, Switzerland, and…
Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
See our Cookie Privacy Policy Here